Difference between revisions of "Atovaquone (Mepron)"
m |
|||
| Line 1: | Line 1: | ||
| − | |||
| − | |||
==General information== | ==General information== | ||
Class/mechanism: Antiprotozoal, antimicrobial. Hydroxy-1,4-naphthoquinone, analog of ubiquinone, with antipneumocystis activity. Exact mechanism unclear, but may involve inhibition of the electron transport chain in mitochondria and downstream inhibition of nucleic acid and ATP synthesis.<ref name="insert">[http://us.gsk.com/products/assets/us_mepron.pdf Atovaquone (Mepron) package insert]</ref><ref>[[Media:Atovaquone.pdf | Atovaquone (Mepron) package insert (locally hosted backup)]]</ref> | Class/mechanism: Antiprotozoal, antimicrobial. Hydroxy-1,4-naphthoquinone, analog of ubiquinone, with antipneumocystis activity. Exact mechanism unclear, but may involve inhibition of the electron transport chain in mitochondria and downstream inhibition of nucleic acid and ATP synthesis.<ref name="insert">[http://us.gsk.com/products/assets/us_mepron.pdf Atovaquone (Mepron) package insert]</ref><ref>[[Media:Atovaquone.pdf | Atovaquone (Mepron) package insert (locally hosted backup)]]</ref> | ||
| Line 9: | Line 7: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| − | + | ''No known antineoplastic properties.'' | |
| − | |||
==Patient drug information== | ==Patient drug information== | ||
| Line 21: | Line 18: | ||
[[Category:Antimicrobial]] | [[Category:Antimicrobial]] | ||
[[Category:PCP prophylaxis]] | [[Category:PCP prophylaxis]] | ||
| − | + | ||
| − | [[Category: | + | [[Category:Drugs FDA approved in 1992]] |
Revision as of 14:09, 1 November 2014
General information
Class/mechanism: Antiprotozoal, antimicrobial. Hydroxy-1,4-naphthoquinone, analog of ubiquinone, with antipneumocystis activity. Exact mechanism unclear, but may involve inhibition of the electron transport chain in mitochondria and downstream inhibition of nucleic acid and ATP synthesis.[1][2]
Route: PO (typically as liquid suspension)
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
No known antineoplastic properties.